Abstract
Introduction Screening for G6PD deficiency can inform disease management including malaria. Treatment with the antimalarial drugs primaquine and tafenoquine can be guided by point-of-care testing for G6PD deficiency.
Methods and Findings Data from similar clinical studies evaluating the performance of the STANDARD™ G6PD Test (SD Biosensor, South Korea) conducted in Bangladesh, Brazil, Ethiopia, India, Thailand, the United Kingdom, and the United States were pooled. Test performance was assessed in a retrospective analysis on capillary and venous specimens. All study sites used spectrophotometry for reference G6PD testing, and either the HemoCue or complete blood count for reference hemoglobin measurement.
The sensitivity of the STANDARD™ G6PD Test using the manufacturer thresholds for G6PD deficient and intermediate cases in capillary specimens from 4212 study participants was 100% (95% Confidence Interval (CI): 97.5%–100%) for G6PD deficient cases with <30% activity and 77% (95% CI 66.8%– 85.4%) for females with intermediate activity between 30%–70%. Specificity was 98.1% (95% CI 97.6%–98.5%) and 92.8% (95% CI 91.6%–93.9%) for G6PD deficient individuals and intermediate females, respectively. The majority (12/20) of G6PD intermediate females with false normal results had activity levels >60% on the reference assay. Negative predictive values for females with G6PD activity >60% was 99.6% (95% CI 99.1%–99.8%) on capillary specimens. Test sensitivity among 396 P. vivax malaria cases was 100% (69.2%–100.0%) for both deficient and intermediate cases. In the study population, a high proportion of those classified as G6PD deficient or intermediate resulted from true normal cases. Despite this, the majority cases would receive the correct medication and no true G6PD deficient cases would be treated inappropriately.
Conclusions The STANDARD G6PD Test enables safe access to drugs which are contraindicated for individuals with G6PD deficiency. Operational considerations will inform test uptake in specific settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Brazil, Ethiopia, India, Thailand, UK, and US studies were funded by the United Kingdom’s Foreign, Commonwealth & Development Office (FCDO), grant number 204139 and, by the Bill & Melinda Gates Foundation [OPP1107113, OPP1054404 and OPP1164105]. The FCDO and Bill & Melinda Gates Foundation awards to PATH support the availability of point-of-care tests for G6PD deficiency. GB, CSC, and FN work at the Shoklo Malaria Research Unit, part of the Mahidol Oxford University Research Unit supported by the Wellcome Trust Mahidol Major Overseas Programme–Thailand Unit (Grant Number 220211). For the purpose of Open Access, the authors have applied a CC BY public copyright license to any author accepted manuscript version arising from this submission RNP and the Bangladesh study were funded by the Wellcome Trust (Senior Fellowship in Clinical Science, 200909), BL is funded by the Australian Department of Foreign Affairs and Trade, RNP is funded by the Bill & Melinda Gates Foundation (OPP1054404 and OPP1164105). MVGL and WMM are funded by Brazilian CNPq. Under the grant conditions of the Gates Foundation, a Creative Commons Attribution 4.0 Generic License has been assigned to the Author Accepted Manuscript version that might arise from this submission. The findings and conclusions contained within are those of the authors and do not necessarily reflect the positions of FCDO or the Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Studies were reviewed and approved by the following ethical committees. Ethical review committee (ERC) and research review committee (RRC) of the icddrb. Australian Human Research Ethics Committee (HREC) of the Northern Territory. PATH Research Ethics Committee. Ethics Committee Board of Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado. Brazil National Research Ethics Commission. Ethiopian National Research Ethics Review Committee. Medical College of Kolkata Institutional Ethics Committee. Indian Council for Medical Research (ICMR)- National Institute of Cholera and Enteric Disease Institutional Ethics Committee. Mahidol University Faculty of Tropical Medicine and the University of Oxford Tropical Research Ethics Committee. Western Institutional Review Board. Fred Hutchinson Cancer Research Center institutional review board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data from all published studies can be found in the specific publications, as well as in the Harvard Dataverse. Relevant identifiers include the following: Domingo, Gonzalo, 2021, "Fingerstick equivalence and blood disorder interference evaluation of a point-of-care test for G6PD deficiency", https://doi.org/10.7910/DVN/GLLPV9, Harvard Dataverse, V1, UNF:6:KJgifE7Ub32PNxyMZK49Pw== [fileUNF] Zobrist, Stephanie, 2021, "Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil", https://doi.org/10.7910/DVN/KLUZTX, Harvard Dataverse, V2
